MediWound Ltd. released a company presentation highlighting its enzymatic therapeutics platform for non-surgical tissue repair, featuring NexoBrid and the investigational candidate EscharEx. The presentation notes NexoBrid is approved in the U.S., EU and Japan for eschar removal in severe burns and reports 2025 revenue of $17 million. MediWound also outlines EscharEx development for debridement and facilitation of wound closure in chronic wounds, including a Phase 3 program in venous leg ulcers, with additional trials planned for diabetic foot ulcers and pressure ulcers in 2026. The presentation includes balance sheet figures showing $54 million in cash and no debt as of Dec. 31, 2025, and discusses manufacturing capacity expansion with regulatory approvals expected in 2026, along with collaborations including Vericel, Mölnlycke, Kaken, BARDA and the U.S. Department of Defense. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.